January 9, 2018 / 4:28 PM / a year ago

BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019

Jan 9 (Reuters) - Bluebird Bio Inc:

* BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019

* BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018

* BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019 Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below